A

Avalo Therapeutics

AVTX

11.170
USD
-0.58
(-4.94%)
مغلق
حجم التداول
9,477
الربح لكل سهم
0
العائد الربحي
0
P/E
-0
حجم السوق
121,929,000
الأخبار المقالات

العنوان: Avalo Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).